An observational study in Subarachnoid Hemorrhage, Aneurysmal, Delayed Cerebral Ischemia and Vasospasm, Cerebral, sponsored by Medical University of Vienna. Recruiting at 1 site in Austria. Open to participants aged 18 Years to 95 Years. Per ClinicalTrials.gov, last updated 2023-10-19.
Sponsored by Medical University of Vienna · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Subarachnoid Hemorrhage with a site in Austria — 3 open to participants now, 3 under way, none of them phase 3. Subarachnoid Hemorrhage · Austria.
Among the 14 studies in Subarachnoid Hemorrhage with a site in Austria, this one is one of 5 that started in 2020, is one of 4 observational ones, and was the 12th registered.
513 studies on the registry are indexed under Subarachnoid Hemorrhage; 131 are open to participants now.
Browse Subarachnoid Hemorrhage studies →3 of the 14 studies in Subarachnoid Hemorrhage with a site in Austria are open now. Recruiting first, the newest first:
Medical University of Vienna · Sites in Austria
Ages 18–80
Medical University Innsbruck · Sites in Austria
Ages 18–90
A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →
Of the 92 Subarachnoid Hemorrhage studies recruiting now, 58 (63%) set no upper age limit and 5 (5%) stop at 75 or younger; 8 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 95 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 120 across 227 observational studies indexed under Subarachnoid Hemorrhage.
Median enrollment 247 across the 10 interventional studies, 80 across the 4 observational. Of the 10 that completed or were terminated, 3 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 14 have an industry lead sponsor. The 10 most frequent:
Medical University of Vienna is the lead sponsor of 1,111 studies on the registry; 186 are open to participants now.
Medical University of Vienna has 2 studies filed under Subarachnoid Hemorrhage — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Subarachnoid Hemorrhage with a site in Austria, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Nimodipine reduces the risk of poor outcome and delayed cerebral ischemia in patients suffering aneurysmal subarachnoid haemorrhage (SAH), but its mode of action is unknown. Its beneficial effect is assumed to be due its neuroprotective effects by reducing intracellular calcium and thereby cellular apoptosis, but higher concentrations might induce marked systemic hypotension, thereby inducing cerebral ischemia. Since several dosing regimes and routes of administration with inconclusive superiority exist and since the target site concentration of nimodipine - the unbound drug concentrations beyond the blood-brain barrier - is still not known, it is reasonable to measure nimodipine concentrations within the blood, cerebrospinal fluid (CSF) and interstitial brain tissue following oral, intra-venous and intra-arterial administration and correlate intra-arterial nimodipine administration to measures of cerebral metabolism and oxygenation.
Therefore, the investigators propose to investigate in 30 patients suffering severe aneurysmal SAH and requiring cerebral microdialysis for cerebral neurochemical monitoring:
Patients requiring intensive care and bedside cerebral microdialysis for cerebral neurochemical monitoring as standard care with a clinical indication for concomitant treatment with either oral, intra-venous or intra-arterial nimodipin
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
60mg of nimodipine is orally administered every 4 h,
Drug: Nimodipine
nimodipine is continuously administered intra-venously, starting with 0.5 mg/h on day 1 and increased every day for 0.5 mg/h to a maximum dose of 2.0mg/h on day 4
Drug: Nimodipine
during endovascular procedure 2mg of nimodipine is infused via a microcatheter into the internal carotid artery for 20 minutes
Drug: Nimodipine
If application of nimodipine is clinically indicated patients will be enrolled in the study protocol according to the inclusion and exclusion criteria. The clinically appropriate route of administration will be administered according to the recommended regimen of the study drug; i.e. within the first 10-14 days intra-venous infusion and thereafter oral administration. Intra-arterial infusion will be performed due to severe cerebral vasospasm with impending stroke.
cerebral nimodipine concentrations
Area under the concentration-time curve in brain, cerebrospinal fluid and serum, dependent on the route of administration (i.e. oral, intra-venous, and intra-arterial)
Time frame: during the intervention
cerebral ethanol concentrations
Area under the concentration-time curve and maximum concentrations in brain tissue, CSF and blood after intravenous administration
Time frame: during the intervention
cerebral lactate/pyruvate ratio (LPR)
determined by cerebral microdialysis
Time frame: during the intervention for oral and intravenous administered nimodipine, 12 hours after the intervention for intra-arterial nimodipine administration
brain tissue oxygen tension (pbtO2)
determined by cerebral parenchymal probes
Time frame: during the intervention for oral and intravenous administered nimodipine, 12 hours after the intervention for intra-arterial nimodipine administration
cardiac output
measured by Pulse Contour Cardiac Output (PiCCO) monitoring
Time frame: during the intervention
fluid responsiveness
measured by Pulse Contour Cardiac Output (PiCCO) monitoring
Time frame: during the intervention
extravascular lung water index
measured by Pulse Contour Cardiac Output (PiCCO) monitoring
Time frame: during the intervention
systemic vascular resistance index
measured by Pulse Contour Cardiac Output (PiCCO) monitoring
Time frame: during the intervention
transcranial doppler flow velocities
measured in the middle cerebral artery ipsilateral to the microdialysis probe
Time frame: during the intervention for oral and intravenous administered nimodipine, 12 hours after the intervention for intra-arterial nimodipine administration
angiographic vasospasm
mild: vessel diameter from 60-99%, moderate: vessel diameter from 30-59%, severe: vessel diameter \<30% of the physiological lumen
Time frame: immediately after the intervention
cerebral perfusion pressure
measured continuously via intra-arterial and intracranial probes
Time frame: during the intervention for oral and intravenous administered nimodipine, 12 hours after the intervention for intra-arterial nimodipine administration
incidence of delayed ischemic strokes
ischemic strokes on CT scans
Time frame: 3-21 days following subarachnoid haemorrhage
Started Nov 2020 (actual). Primary completion is estimated for Jul 2024, 44 months after the start.
Of 117 non-industry observational studies under Subarachnoid Hemorrhage, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 127. This study's planned 44 months is close to that.
Counting every sponsor, half of 120 studies reached it within 40 months; a quarter within 19 and three quarters within 127.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Vienna →